



Institutional Biosafety Committee Meeting Minutes

The meeting was called to order on 5/19/2026 at 11:30AM. A quorum was present. The meeting was held via Zoom and in-person (Melville Library – 5th Floor, Room W5530). The meeting was open.

Attendance

Voting Members Present:

Nicholas Carpino
Jeronimo Cello
Hwan Kim
Christopher Kuhlow
Dafang Wang

Non-Voting Attendees, Staff and Guests Present:

Rebecca Dahl
Lu-Ann Kozlowski
Aimee Minton
Terrence Rusch
Abdool Samad

Recording:

Erin Augello

Items

1. Meeting called to order at 11:30AM

2. Next meeting date and general announcements

The next meeting date is 6/23/2026. Dr. Carpino surveyed the assembled group to assess any conflict of interest or quorum issues. Members should recuse themselves and leave the room or Zoom meeting during the review of a study on which they have a conflict of interest.

3. Review of minutes from last meeting

Review type: Full Committee Review

Action: **Approved**
Effective date: **5/19/2026**
Vote: **Total = 5; For = 5; Opposed = 0; Abstained = 0**

4. Continuing reviews requiring IBC review

This section was reviewed and noted by the committee.

5. New studies for committee review

a. PROTO202600016 Therapeutic Targets in Kidney Disease

PI:	Jiyoung Kim
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	American Heart Association Incorporated, Grant Office ID: Funding Source ID: 26CDA1613910
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required

Modifications (If Applicable):

i. In Section: Basic Information

Item 4. Please briefly describe rsNAM work proposed in this protocol.

ii. In Section: Biosafety summary

Item 1. As no Select Agents or Toxins are utilized in this protocol, remove Select Agents and Toxins from the Biosafety Summary list and any references / information from other sections of the protocol.

iii. In Section: Tissue, Blood, or Body Fluids

Item 1. Animal tissues are generally appropriate for handling under BSL-1/ABSL-1 containment.

iv. In Section: Select Agents and Toxins

Item 1. No select agent is used in this protocol. All information in this section should be deleted

v. In Section: Biohazards

Item 1. Please clarify “N/a” in Row 2. Otherwise delete this information

vi. In Section: Recombinant or Synthetic Nucleic Acid Work Description

Item 1. Please provide specific details of rsNAM work that will be conducted. The information provided is very generalized.

vii. In Section: Exposure Assessment and Protective Equipment

The response is not fully responsive to the question, which requests a description of the potential consequences of exposure or release of the agents used in this protocol. Much of the response focuses on biosafety procedures, decontamination, training, and spill response rather than biological consequences of exposure. This description should be removed from this section. In addition, the discussion of possible “recombination events” and virus production is unclear, particularly since no viral vector work appears to be described elsewhere in the protocol. Please clarify whether any viral vectors are being used. If not, this discussion should be removed. Finally, while the response acknowledges the possibility of exposure to bloodborne pathogens

from human cell lines, it does not describe the potential consequences of such exposure (e.g., infection with HIV, HBV, HCV, or other human pathogens). Please revise the section accordingly.

Effective Date: 5/21/2026

Project Expiration: 5/20/2027

Votes:

For:	5
Against:	0
Recused:	0
Absent:	4
Abstained:	0

6. Amendments requiring IBC review

a. AMEND202600049 Full application - 2026

PI:	Lonnie Wollmuth
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications required

Modifications (If Applicable):

i. In Section: Viruses and Prions

Item 1. For theoretical recombination/helper contamination concerns, AAV vector production in HEK293 cells can be conducted under BSL-2 practices. However, please be aware that purified recombinant AAV preparations lacking helper virus and hazardous transgenes are generally appropriate for handling under BSL-1/ABSL-1 containment.

ii. In Section: Select Agents and Toxins

Item 4. Please include volume / concentration of TTX to be used.

iii. In Section: Exposure Assessment and Protective Equipment

Item 1. Please acknowledge low possibility of generating replication competent lentivirus. In addition, along with recognizing the potential consequences of exposure to lentivirus, consequences of exposure to AAV should be described, including risks associated with potential insertional mutagenesis.

Item 4. Please note, BSC certification is due in less than a month.

Effective Date: 6/13/2026

Project Expiration: 6/12/2026

Votes:

For:	5
Against:	0
Recused:	0
Absent:	4
Abstained:	0

b. AMEND202600051 Change in personnel and updated funding info

PI:	Chiara Luberto
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required**Modifications (If Applicable):**

i. In Section: Protocol team members

Item 1. Emma Downey is listed as an undergraduate student, but is also mentioned as a graduate student. Similarly, Etkin Akar is listed as an undergraduate student. Clarification is required – are they undergraduate students or graduate students?

ii. In Section: Primary Cells or Cell Lines

Item 1. CD34 positive hematopoietic cells are listed twice. Please remove one of the listings. Additionally, information about production of lentiviral particles should be deleted in this section.

Item 2. There are additional cell lines indicated in this section. If they are to be used, then they should be listed within the response to Item 2 on the “Biohazards” page.

iii. In Section: Exposure Assessment and Protective Equipment

Item 1. Please address the potential consequences of exposure to bloodborne pathogens (e.g., HIV, HBV, HCV) when handling human cell lines.

iv. In Section: Waste Management

Item 1. Indicate contact time of bleach for decontamination treatment.

Effective Date: 5/26/2026

Project Expiration: 5/25/2027

Votes:

For:	5
Against:	0
Recused:	0
Absent:	4
Abstained:	0

c. AMEND202600056 OCT and Fluorescence Imaging of rodents in vivo

PI:	Yingtian Pan
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	Laboratory staff need to complete ELS 003
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required**Modifications (If Applicable):**

- i. Training is not up to date. Pan, Du, Jeong, Nadkarni and Wang require ELS 003. Please ensure training is accomplished.
- ii. In Section: Amendment Request
 - Item 4. Please describe the changes within the Amendment.
 - Item 5. Please identify the scientific or procedural justification for the proposed changes.
- iii. In Section: Basic Information
 - Item 4. Please provide more detail, including description of work with rsNAM.
- iv. In Section: Funding Sources
 - Item 1. RF funding ID missing. Please provide, as requested.
- v. In Section: Biosafety summary
 - Item 1. Due to the use of viruses, please select “Viruses and Prions” option from the dropdown menu and fill out the requested information on the “Viruses and Prions” page.
- vi. In Section: Tissue, Blood, or Body Fluids
 - Item 1. 1. ‘Viral vectors’ should be removed from the “Agent” column. If cells or cells lines are used in the protocol, please list them here
 - Items 2 and 3. Delete information provided since is refers to viral vectors.
- vii. In Section: Biohazards
 - Item 1. For the entry “Viral Vectors,” the ‘Type’ column should not have "Tissue" listed.
- viii. In Section: Recombinant or Synthetic Nucleic Acid Work Description
 - Item 3. Commentary in last paragraph is not relevant to the question being asked. Please remove it.
- ix. In Section: Exposure Assessment and Protective Equipment
 - Item 1. Describe consequences of exposure to AAV (insertional mutagenesis). Although the risk and chances are low, AAV can theoretically cause insertional mutagenesis. Please include this information here.
 - Item 4. BSC certification has expired. Please recertify cabinet and provide new certification date.
- x. In Section: Dual Use Research
 - Item 2. The response stems from a misconstrued understanding of dual use research. Please remove.
- xi. In Section: Waste Management
 - Item 1. Include information related to disinfectants, concentration and contact time to be used.
 - Item 3. Do not use 10% bleach if attempting to remove spill, splash or contamination to eyes, face, skin, etc.

Effective Date: 4/24/2026

Project Expiration: 4/23/2027

Votes:

For:	5
Against:	0
Recused:	4
Absent:	0
Abstained:	0

d. AMEND202600061 Mechanisms of Ciliogenesis

PI:	Ken-Ichi Takemaru
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	Laboratory staff need to complete ELS 003 and EOS 004
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required

Modifications (If Applicable):

i. Training is not up to date. Takemaru, Li, Pan, Kim, Chen require ELS 003 and EOS 004.

Please ensure training is accomplished.

ii. In Section: Basic Information

Item 4. Please briefly describe rsNAM work proposed in this protocol.

iii. In Section: Primary cells or cell lines

Item 1. BSL-2+” is not a formally defined biosafety level. Please clarify the specific enhanced practices or containment measures associated with the proposed lentiviral work or revise the classification to standard BSL-2.

iv. In Section: Viruses or prions

Item 1. BSL-2+” is not a formally defined biosafety level. Please clarify the specific enhanced practices or containment measures associated with the proposed lentiviral work or revise the classification to standard BSL-2.

v. In Section: Biohazards

Item 1. BSL-2+” is not a formally defined biosafety level. Please clarify the specific enhanced practices or containment measures associated with the proposed lentiviral work or revise the classification to standard BSL-2.

vi. In Section: Exposure Assessment and Protective Equipment

Item 1. The response is incomplete and should be revised. E. coli K-12 strains are RG1 organisms and should not be described as potentially infectious in the same way as lentiviral vectors or human cell lines. Additionally, please describe the specific consequences of exposure to the second-generation, VSV-G–pseudotyped lentiviral vector, including transduction of dividing and non-dividing cells, insertional mutagenesis, and the low but possible generation/exposure to replication-competent lentivirus (RCL), which could cause HIV-like infection. Finally, please address the potential consequences of exposure to bloodborne pathogens (e.g., HIV, HBV, HCV) when handling human cell lines.

Item 4. Please be aware that certification of BSC expires on 5/22/2026. Annual certification is due soon.

Effective Date: 5/28/2026

Project Expiration: 5/27/2027

Votes:

For:	5
Against:	0
Recused:	4
Absent:	0
Abstained:	0

7. Review of incidents

None

8. Review of other agenda items

None

9. Inspection results

All inspections and responses were summarized by Mr. Kuhlow and reviewed and noted by the committee.

10. Discussion items/readings (major and minor points of order)

i. Discussion was had regarding where to add the NIH information for all new studies. Principal Investigator’s need to verify that they have read the information from the NIH link prior to approval. The IBC Coordinator will contact IT to get the link added into myResearch Safety. The committee was in agreement that the best place to do this was to add a question to the electronic system. Once the PI has read the information, he/she will click "yes" prior to submitting the study.

ii. The committee discussed that the current chair is stepping down. Dr. Carpino will remain on the committee. Another committee member (Dr. Kim) has agreed to be the new chair. The change in leadership will begin June 1, 2026. Dr. Carpino has trained Dr. Kim in the review process and the information that needs to be discussed at the meetings. Additionally, the new chair has received training regarding how to provide that information to the IBC Coordinator.

11. Meeting adjourned at 12:11 PM